ATE548463T1 - Lrrk2 polypeptidesubstrate und ihre verwendungen - Google Patents

Lrrk2 polypeptidesubstrate und ihre verwendungen

Info

Publication number
ATE548463T1
ATE548463T1 AT09252042T AT09252042T ATE548463T1 AT E548463 T1 ATE548463 T1 AT E548463T1 AT 09252042 T AT09252042 T AT 09252042T AT 09252042 T AT09252042 T AT 09252042T AT E548463 T1 ATE548463 T1 AT E548463T1
Authority
AT
Austria
Prior art keywords
lrrk2
compound
polypeptide
protein kinase
kinase activity
Prior art date
Application number
AT09252042T
Other languages
English (en)
Inventor
Dario Alessi
R Jeremy Nichols
Original Assignee
Medical Res Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/244,715 external-priority patent/US7947468B2/en
Application filed by Medical Res Council filed Critical Medical Res Council
Application granted granted Critical
Publication of ATE548463T1 publication Critical patent/ATE548463T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
AT09252042T 2008-09-18 2009-08-24 Lrrk2 polypeptidesubstrate und ihre verwendungen ATE548463T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0817106A GB2463656B (en) 2008-09-18 2008-09-18 Substrate of LRRK2 and methods of assessing LRRK2 activity
US12/244,715 US7947468B2 (en) 2007-04-05 2008-10-02 Methods

Publications (1)

Publication Number Publication Date
ATE548463T1 true ATE548463T1 (de) 2012-03-15

Family

ID=39951808

Family Applications (1)

Application Number Title Priority Date Filing Date
AT09252042T ATE548463T1 (de) 2008-09-18 2009-08-24 Lrrk2 polypeptidesubstrate und ihre verwendungen

Country Status (7)

Country Link
EP (1) EP2199405B1 (de)
JP (1) JP5002730B2 (de)
AT (1) ATE548463T1 (de)
CA (1) CA2737507A1 (de)
DK (1) DK2199405T3 (de)
GB (1) GB2463656B (de)
WO (1) WO2010031988A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8367349B2 (en) 2010-04-19 2013-02-05 Medical Research Council Methods for identifying modulators of LRRK2
GB2479799B (en) * 2010-04-19 2012-09-19 Medical Res Council Methods for assessing LRRK2 inhibitors
US9233977B2 (en) 2010-10-29 2016-01-12 Merck Sharp & Dohme Corp. Leucine-rich repeat kinase enzyme activity
EP2710041A4 (de) 2011-05-18 2014-11-05 Parkinson S Inst Assay zur bestimmung der lrrk2-aktivität bei morbus parkinson
EP2867236B1 (de) 2012-06-29 2017-06-14 Pfizer Inc Neue 4-(substituierte amino)-7h-pyrrolo[2,3-d]pyrimidine als lrrk2 hemmer
WO2015092592A1 (en) 2013-12-17 2015-06-25 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
KR102161364B1 (ko) 2015-09-14 2020-09-29 화이자 인코포레이티드 LRRK2 억제제로서 이미다조[4,5-c]퀴놀린 및 이미다조[4,5-c][1,5]나프티리딘 유도체
CN108709997B (zh) * 2018-05-28 2020-09-18 中国林业科学研究院林业研究所 Lrr受体激酶的底物寻找方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1866433T3 (da) * 2006-03-14 2009-08-17 Cellzome Ag Fremgangsmåde til identifikation af LRRK-2interagerende molekyler og til rensning af LRRK2
WO2008091799A2 (en) * 2007-01-22 2008-07-31 The Trustees Of Columbia University In The City Of New York Cell-based methods for identifying inhibitors of parkinson's disease-associated lrrk2 mutants
GB0706709D0 (en) * 2007-04-05 2007-05-16 Medical Res Council Methods

Also Published As

Publication number Publication date
EP2199405A2 (de) 2010-06-23
GB2463656A (en) 2010-03-24
GB2463656B (en) 2010-10-13
EP2199405B1 (de) 2012-03-07
JP2012502645A (ja) 2012-02-02
GB0817106D0 (en) 2008-10-29
EP2199405A3 (de) 2010-09-15
WO2010031988A3 (en) 2010-09-23
WO2010031988A2 (en) 2010-03-25
CA2737507A1 (en) 2010-03-25
DK2199405T3 (da) 2012-04-10
JP5002730B2 (ja) 2012-08-15

Similar Documents

Publication Publication Date Title
ATE548463T1 (de) Lrrk2 polypeptidesubstrate und ihre verwendungen
WO2008122789A3 (en) Methods for modulating lrrk2
DK2158319T3 (da) Knoglemålrettet alkalisk fosfatase, kits og fremgangsmåder til anvendelse deraf
DE602007001103D1 (de) Verfahren zur identifizierung von lrrk2 interagierenden molekülen und zur reinigung von lrrk2
BRPI0513477A (pt) composições e processos de uso de proteìna 4 semelhante a angiotensina
ATE489482T1 (de) Verfahren zur herstellung von hybridsubstraten mit dna und antikörpern sowie verwendungen davon
EA200702452A1 (ru) Способ модуляции стресс-активированной протеинкиназной системы
ATE520682T1 (de) 2-heteroarylaminopyrimidinderivate als kinaseinhibitoren
ATE470864T1 (de) Verfahren zur quantifizierung von allergenen
ATE328112T1 (de) Anaplastisches lymphoma kinase testverfahren, reagenzien und kompositionen davon
ATE495442T1 (de) Zusammensetzungen und verfahren zur erkennung von sirolimus
NO20090993L (no) BIQ-markorer for vurdering av leverfunksjon
SE0202157D0 (sv) Methods for identification of compounds modulating insulin resistance
ATE487721T1 (de) Triaza-benzoäeüazulenderivate zur behandlung von tumoren
ATE495243T1 (de) Verfahren zur herstellung von hochempfindlichen endonukleasen, neuartige zubereitungen von nukleasen und ihre verwendung
DE602007008565D1 (de) Verfahren zur identifizierung von modulatoren der eoxin-bildung
SG129428A1 (en) Generic kinase assay
ATE405369T1 (de) Optisches element sowie verfahren zur erfassung von strahlparametern, mit einem als pixels-matrix ausgebildeten temperatursensor
ATE456797T1 (de) Verwendung von nogo-c bei der beurteilung von herzversagen
ATE529747T1 (de) Verfahren zur bestimmung der transportaktivität eines transportproteins
ATE501252T1 (de) Verfahren zur inhibierung von tumorzellwachstum mit foxm1 sirns
DE602006015276D1 (de) Mikroarray-Substrat, Verfahren zu dessen Herstellung, Mikroarray mit dem Mikroarray-Substrat und Verfahren zur Analyse von Zielmolekülen unter Verwendung des Mikroarrays
WO2005088306A3 (en) Biologically-active dna-binding sites and related methods
ATE530907T1 (de) Verfahren zur beurteilung der hemmungsaktivität von antikörpern gegen insulinartigen wachstumsfaktor-1-rezeptor
WO2007010219A3 (en) Methods for modulating a wnk i soform protein kinase activity